All In Biotech

Drug Trial Radar · NCT00720941

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,110

Actual

Start

Aug 14, 2008

Primary completion

May 21, 2012

Study completion Mar 24, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • PazopanibDrug

    800 mg administered once daily orally continuous dosing

  • SunitinibDrug

    50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: From randomization until the earliest date of disease progression or date of death from any cause, assessed up to approximately 39 months

Locations

227 sites in 14 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Escondido, California

  • Novartis Investigative Site

    Fresno, California

  • Novartis Investigative Site

    Greenbrae, California

  • Novartis Investigative Site

    Hayward, California

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Montebello, California

  • Novartis Investigative Site

    Oakland, California

  • Novartis Investigative Site

    Orange, California

  • Novartis Investigative Site

    Roseville, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Bernardino, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    San Jose, California

  • Novartis Investigative Site

    Santa Clara, California

  • Novartis Investigative Site

    South San Francisco, California

  • Novartis Investigative Site

    Vallejo, California

  • Novartis Investigative Site

    Walnut Creek, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Southington, Connecticut

  • Novartis Investigative Site

    Trumbull, Connecticut

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Fort Myers, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Elk Grove Village, Illinois

  • Novartis Investigative Site

    Maywood, Illinois

  • Novartis Investigative Site

    Peoria, Illinois

  • Novartis Investigative Site

    Carmel, Indiana

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Cedar Rapids, Iowa

  • Novartis Investigative Site

    Louisville, Kentucky

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.